The Cigna Group (CI) Valuation
Historical valuation analysis based on 1280 data points (2021-09-13 to 2026-10-16)
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are...
The Cigna Group (CI) currently trades at a P/E ratio of 12.45 (historical range: 7.89–33.64, median: 14.99), placing it at the 34th percentile — below its historical average, P/S ratio of 0.28 (range: 0.25–0.59, 17th percentile — cheap relative to its history), EV/EBITDA of 10.31 (range: 8.21–15.90, 10th percentile).
Over the historical period (2021-09-13 to 2026-10-16), The Cigna Group's P/E ratio has expanded by 40% over the observed period (from an average of 13.7 to 19.1).
The Cigna Group trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 12.45 | 14.99 | 34th | below its historical average |
| P/S Ratio | 0.28 | 0.44 | 17th | cheap relative to its history |
| EV/EBITDA | 10.31 | 13.10 | 10th | cheap relative to its history |
| FCF Yield | 11.55% | 12.23% | 24th | above its historical average |
The Cigna Group (CI) Valuation & P/E History
The Cigna Group (CI) is a US-listed stock operating in the Healthcare sector, specifically the Healthcare Plans industry currently trading at $302.30 with a market capitalization of $79.9 billion. This page provides historical valuation analysis for CI based on 1280 data points covering 2021-09-13 to 2026-10-16. The P/E ratio of 12.45 is below the historical median of 14.99, placing CI at the 34th percentile of its valuation range. The P/S ratio of 0.28 compares to a median of 0.44.
CI Valuation Metrics & Historical Range
The valuation table above shows The Cigna Group's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether CI is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests CI is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for The Cigna Group.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is CI Overvalued or Undervalued?
The Cigna Group trades well below its historical valuation range across most metrics. The overall valuation percentile of 20 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive CI is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full CI analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.CI trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.